AR111409A1 - SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINES - Google Patents

SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINES

Info

Publication number
AR111409A1
AR111409A1 ARP180100849A ARP180100849A AR111409A1 AR 111409 A1 AR111409 A1 AR 111409A1 AR P180100849 A ARP180100849 A AR P180100849A AR P180100849 A ARP180100849 A AR P180100849A AR 111409 A1 AR111409 A1 AR 111409A1
Authority
AR
Argentina
Prior art keywords
splice variant
nucleic acid
chemotherapeutic agents
gene
oligonucleotides
Prior art date
Application number
ARP180100849A
Other languages
Spanish (es)
Inventor
Shikha Saini
Fei Yue
Aditi Mathur
Sidney Hopps
Bellur Prabhakar
Original Assignee
Jivana Biotechnology Inc
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jivana Biotechnology Inc, Univ Illinois filed Critical Jivana Biotechnology Inc
Publication of AR111409A1 publication Critical patent/AR111409A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos para tratar cánceres, que comprenden administrar una combinación de agentes antineoplásicos, donde la combinación comprende agentes quimioterapéuticos de antraciclinas y una o más moléculas de ácidos nucleicos capaces de regular negativamente la expresión de al menos una variante de empalme del gen IG20, donde todas las variantes de empalme del gen IG20 están reguladas negativamente. En una forma de realización, la variante de empalme del gen IG20 es una variante de empalme MADD y las moléculas de ácidos nucleicos son siARN, ARNhc y oligonucleótidos antisentido que comprenden una secuencia de ácido nucleico complementaria de la secuencia de ácido nucleico del exón 13L de la variante de empalme MADD o un transcripto de ARNm del exón 13L de la variante de empalme MADD. Métodos para tratar cánceres que comprenden aplicar una terapia combinada con moléculas de ácidos nucleicos capaces de regular negativamente la expresión de al menos una variante de empalme del gen IG20 y agentes quimioterapéuticos de antraciclinas.Compositions and methods for treating cancers, comprising administering a combination of antineoplastic agents, wherein the combination comprises chemotherapeutic agents of anthracyclines and one or more nucleic acid molecules capable of negatively regulating the expression of at least one splice variant of the IG20 gene, where All splice variants of the IG20 gene are negatively regulated. In one embodiment, the splice variant of the IG20 gene is a MADD splice variant and the nucleic acid molecules are siRNA, hRNA and antisense oligonucleotides comprising a nucleic acid sequence complementary to the exon 13L nucleic acid sequence of the MADD splice variant or an exon 13L mRNA transcript of the MADD splice variant. Methods for treating cancers that comprise applying a combination therapy with nucleic acid molecules capable of negatively regulating the expression of at least one splice variant of the IG20 gene and anthracycline chemotherapeutic agents.

ARP180100849A 2017-04-24 2018-04-05 SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINES AR111409A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762489056P 2017-04-24 2017-04-24

Publications (1)

Publication Number Publication Date
AR111409A1 true AR111409A1 (en) 2019-07-10

Family

ID=63919814

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100849A AR111409A1 (en) 2017-04-24 2018-04-05 SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINES

Country Status (3)

Country Link
AR (1) AR111409A1 (en)
TW (1) TW201902912A (en)
WO (1) WO2018200144A2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084954A2 (en) * 2006-01-19 2007-07-26 The Board Of Trustees Of The University Of Illinois Selective inhibition of ig20 splice variants to treat cancers

Also Published As

Publication number Publication date
TW201902912A (en) 2019-01-16
WO2018200144A2 (en) 2018-11-01
WO2018200144A3 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
AU2017258642A8 (en) Oligonucleotide analogues targeting human LMNA
CL2017001956A1 (en) Tau antisense oligomers and their use
BR122021025194A8 (en) NUCLEIC ACID MOLECULE, METHOD TO OBTAIN RNA, RNA, METHOD TO OBTAIN A PEPTIDE OR PROTEIN AND IN VITRO OR EX VIVO USES OF RNA
BR112017018954A2 (en) Use of Ras Protein Mutant Form and Method to Treat Cancer
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
PE20171763A1 (en) COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF THE HAO1 GENE (HYDROXIACIDE-OXIDASE 1 (GLYCOLATE-OXIDASE))
AR090641A1 (en) COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GEN ALAS1
AR091539A1 (en) MICRO-ARN miR-15 FAMILY INHIBITORS
CL2020002563A1 (en) Use of fubp1 inhibitors for the treatment of hepatitis b virus infection
PE20181448A1 (en) COMPOSITIONS AND METHODS TO REDUCE THE EXPRESSION OF TAU
CL2021001552A1 (en) Inhibitory double-stranded nucleic acid molecules containing a triloop
EA201791986A1 (en) Oligonucleotides, corresponding to exon 73 of the COL7A1 gene, for the therapy of bulletic epidermolysis
BR112017018329A2 (en) DPP-4 prevention or treatment composition for the calcification of the valve containing the inhibitor
CL2021002842A1 (en) Inhibitory double-stranded nucleic acid molecules with shortened sense strands
MX2019003070A (en) Combination therapy with liposomal antisense oligonucleotides.
AR111409A1 (en) SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS OF ANTHRACICLINES
MX2022009870A (en) Rnas for complement inhibition.
AR111587A1 (en) SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND RENTING CHEMOTHERAPEUTIC AGENTS
AR120341A1 (en) COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTINE (HTT) AND THEIR METHODS OF USE
AR111410A1 (en) SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPEUTIC AGENTS INHIBITORS OF PROTEIN KINASES
MX2017014855A (en) Antisense oligonucleotides to treat dystrophic epidermolysis bullosa.
WO2016107933A3 (en) Materials and methods for the treatment of cancers
CO2020010226A2 (en) Oligonucleotide therapy for wilson's disease
AR111449A1 (en) SYNERGIC COMBINATION OF OLIGONUCLEOTIDES OF NUCLEIC ACIDS AND CHEMOTHERAPY WITH TAXANOS
AR125447A2 (en) SERPINA1 RNAi COMPOSITIONS AND THEIR METHODS OF USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure